Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02691247 · ClinicalTrials.gov registry record · Phase 2

Safety and Efficacy of CLBS03 in Adolescents With Recent Onset Type 1 Diabetes (The Sanford Project T-Rex Study)

A Phase 2 study, sponsored by Lisata Therapeutics.

Completed
Registry status
Phase 2
Development phase
113
Enrollment target

NCT02691247: Completed Phase 2 study, sponsored by Lisata Therapeutics.

NCT02691247 is a Phase 2 study that has completed, run by Lisata Therapeutics. The registered enrollment target is 113 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (15% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02691247, a Phase 2 study, has completed, sponsored by Lisata Therapeutics.

COMPLETED
Registry status
Phase 2
Development phase
113 participants
Enrollment target

Study Summary

This clinical trial will explore the safety and effect of autologous ex vivo expanded polyclonal regulatory T-cells on beta cell function in patients, aged 8 to 17, with recent onset T1DM. Other measures of diabetes severity and the autoimmune response underlying T1DM will also be explored. Eligible subjects will receive a single infusion of CLBS03 (high or low dose) or placebo.

Primary Outcome

The area-under-curve of sequential C-peptide concentrations (AUC-Cpep) during the mixed-meal tolerance test (MMTT) is the gold-standard method to assess residual beta-cell (ie, insulin) secretion in type 1 diabetes.

Interventions

  • BIOLOGICAL Placebo
  • BIOLOGICAL CLBS03 Low Dose
  • BIOLOGICAL CLBS03 High Dose

Trial Details

FieldValue
Enrollment Target 113 participants
Start Date 2016-02
Est. Completion 2020-01
Phase Phase 2
Lisata Therapeutics

12 total trials

What the finished NCT02691247 record still lists

NCT02691247 is an interventional study that assigns participants to a tested intervention. The registered 113 participants enrollment target is mid-sized for trials with a published cap, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (15% lower).

The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.

NCT02691247 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT02691247 about?

NCT02691247 is a clinical study titled "Safety and Efficacy of CLBS03 in Adolescents With Recent Onset Type 1 Diabetes (The Sanford Project T-Rex Study)". This clinical trial will explore the safety and effect of autologous ex vivo expanded polyclonal regulatory T-cells on beta cell function in patients, aged 8 to 17, with recent onset T1DM. Other measures of diabetes severity and the autoimmune response underlying T1DM will also be explored. Eligible...

What is the current status of trial NCT02691247?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 113 participants. The study started on 2016-02. Estimated completion is 2020-01.

What interventions are being tested in trial NCT02691247?

The interventions under investigation include: Placebo (BIOLOGICAL), CLBS03 Low Dose (BIOLOGICAL), CLBS03 High Dose (BIOLOGICAL).

Who is sponsoring clinical trial NCT02691247?

This trial is sponsored by Lisata Therapeutics, which has 12 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT02691247's enrollment target sits among peer trials

113 631st of 2000 higher than 1,370 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00748254 · 113 participants

    Laser-based Photoacoustic Tomography of Human Inflammatory Arthritis

  • NCT04753190 · 113 participants · NA

    Light Timing Study

  • NCT05799248 · 113 participants · Phase 3

    Role of rhPSMA-7.3 PET/CT Imaging in Men With High-Risk Prostate Cancer Following Conventional Imaging and Associated Changes in Medical Management

  • NCT07216105 · 113 participants · Phase 1

    FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02691247, the US trial registry maintained by the National Library of Medicine. NCT02691247 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.